Intellia: Strategic Priorities and Anticipated 2023 Key Milestones

 

• Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platform
• Submit IND application in mid-2023 as part of a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023
• Submit IND application for NTLA-2002 for the treatment of hereditary angioedema (HAE) and initiate global Phase 2 study in 1H 2023
• Present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies
• Progress first CRISPR-based gene insertion investigational therapy in humans; submit IND or equivalent filing for NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD) in 2H 2023
• Ended 2022 in a strong financial position with approximately $1.3 billion in cash

https://www.biospace.com/article/releases/intellia-therapeutics-highlights-strategic-priorities-and-anticipated-2023-key-milestones-/